Molecular Medicine |
Decrease Collagen Synthesis and Increase Matrix Metalloproteinase Activity in Cardiac Fibroblasts In Vitro
From the Myocardial Biology Unit, Whitaker Cardiovascular Institute, Boston University School of Medicine, and Cardiovascular Division, Boston University Medical Center, Boston, Mass.
Correspondence to Wilson S. Colucci, MD, Cardiovascular Division, Boston University Medical Center, 88 East Newton St, Boston, MA 02118. E-mail wilson.colucci{at}bmc.org
| Abstract |
|---|
|
|
|---|
(TNF-
; 100 ng/mL),
IL-6 (10 ng/mL), or interferon-
(IFN-
; 500 U/mL) for 24 hours.
IL-1ß, and to a lesser extent TNF-
, decreased collagen synthesis,
which was measured as collagenase-sensitive
[3H]proline incorporation, but had no effect on cell
number or total protein synthesis. IL-1ß decreased the expression of
procollagen
1(I),
2(I), and
1(III)
mRNA, but increased the expression of procollagen
1(IV),
2(IV), and fibronectin mRNA, indicating a selective
transcriptional downregulation of fibrillar collagen synthesis. IL-1ß
and TNF-
each increased total matrix metalloproteinase (MMP)
activity as measured by in-gel zymography, causing specific increases
in the bands corresponding to MMP-13, MMP-2, and MMP-9. IL-1ß
increased the expression of proMMP-2 and proMMP-3 mRNA, suggesting that
increased metalloproteinase activity is due, at least in part, to
increased transcription. The effects of IL-1ß were not dependent on
NO production. Thus, IL-1ß and TNF-
decrease collagen
synthesis and activate MMPs that degrade collagen. These
observations suggest that IL-1ß and TNF-
may contribute to
ventricular dilation and myocardial failure by promoting
the remodeling of interstitial collagen.
Key Words: inflammatory cytokines interleukin-1ß tumor necrosis factor-
collagen matrix metalloproteinase
| Introduction |
|---|
|
|
|---|
(TNF-
) and interleukin
(IL)1ß are inflammatory cytokines that have been found to
be elevated in failing myocardium from
patients1 and animal models of hemodynamic
overload.2 3 Inflammatory cytokines have been
shown to exert a number of actions that may be important in myocardial
remodeling and failure, including the stimulation of myocyte
hypertrophic growth4 5 6 and the induction of
apoptosis.7 8 9 Another potential mechanism of
myocardial remodeling involves alterations in the extracellular matrix,
resulting in a decrease in the structural integrity of the
myocardium.10 Collagen in the extracellular matrix is the major determinant of myocardial structural integrity.11 The demonstration that there is a reduction in the number of fibrillar collagen tethers in dilated cardiomyopathy led Weber et al12 to suggest that the loss of these tethers was important in the pathogenesis of myocardial dilation by allowing for the slippage of myocytes. The regulation of myocardial collagen turnover involves a dynamic balance between protein synthesis and degradation. Cardiac fibroblasts are the major site for the synthesis of collagen13 14 in the myocardium and also play an important role in the regulation of collagen degradation by matrix metalloproteinases (MMPs).15
In rats, the infusion of TNF-
caused a decrease in myocardial
collagen content.16 In several cell types, inflammatory
cytokines can activate MMPs17 18 or
regulate the activity of tissue inhibitors of
metalloproteinase (TIMPs) that inhibit MMP activity.19
These and other observations have led to the suggestion that
inflammatory cytokines may cause myocardial dilation by
promoting a depletion of interstitial
collagen.16 However, the mechanism by which inflammatory
cytokines might exert this effect has not been delineated. The
purpose of this study was to test the hypothesis that the inflammatory
cytokines exert a net negative effect on collagen turnover by
cardiac fibroblasts. Accordingly, collagen synthesis, collagen mRNAs,
and the activity of MMPs were measured in cultures of neonatal and
adult rat cardiac fibroblasts exposed to IL-1ß, TNF-
, IL-6, or
interferon-
(IFN-
) for 24 hours.
| Materials and Methods |
|---|
|
|
|---|
(100 ng/mL), recombinant
human IL-6 (10 ng/mL), recombinant human IFN-
(500 U/mL) (all
cytokines from R&D Systems), or FBS (10% [vol/vol]; GIBCO).
Control cells were treated with DMEM/PS alone. For experiments testing
the role of NO, fibroblasts were treated in arginine-free DMEM/PS with
or without
NG-monomethyl-L-arginine
(LNMMA, 1 mmol/L, Calbiochem) for 30 minutes before 24-hour
treatment with IL-1ß, or fibroblasts were treated with the vehicle
0.01% (vol/vol) DMSO or with
S-nitroso-N-acetyl-D,L-penicillamine
(SNAP, 100 µmol/L, Alexis) in DMEM/PS for 24 hours.
Collagen Synthesis
Collagenase-sensitive
[3H]proline incorporation was determined by a
modification of the technique described by Botstein et
al.22 Briefly, 10 µCi/mL
[3H]proline (DuPont NEN) and 50 µg/mL
ascorbate (Sigma) were added for the final 4 hours of cytokine
treatment. Cells and media were collected by scraping, and proteins
were precipitated overnight in 20% (wt/vol) trichloroacetic acid at
4°C. Precipitated proteins were washed and digested with
chromatographically purified collagenase (0.5
mg/mL; Worthington Biochemical Corp) and calculated as the percentage
of total protein synthesis sensitive to collagenase, as
described by Guarda et al.23
Total Protein Synthesis
Fibroblasts were plated on 24-well plates and treated with
IL-1ß, TNF-
, IL-6, or IFN-
for 24 hours in the presence of 1
µCi/mL [3H]leucine (DuPont NEN) as previously
described.4 Cell number was determined in parallel plates,
and [3H]leucine incorporation is
presented as disintegrations per minute (dpm) per 1000
cells.
In-Gel Zymography
MMP activity was determined in conditioned media from
fibroblasts treated with IL-1ß, TNF-
, IL-6, or IFN-
for 24
hours in 100-mm dishes. Lyophilized conditioned medium was resuspended
in 1/20 volume of water, and protein was determined by the Bradford
assay (Bio-Rad protein dye reagent) against a BSA standard. MMP
activity per 500 ng protein was measured by in-gel zymography with
gelatin (type A from porcine skin; Sigma) as the substrate as described
by Guarda et al.23 Unstained, digested regions
representing MMP activity were quantified using an imaging
densitometer (GS700, Bio-Rad). MMP identity was determined by estimated
molecular weights against prestained molecular weight markers
and by the ability of metal chelators (10 mmol/L EDTA or 1
mmol/L 1,10-phenanthroline) but not a serine protease
inhibitor (5 mmol/L PMSF) to inhibit
activity.
Assessment of mRNA Levels
Fibroblasts plated on 100-mm dishes were treated with IL-1ß
for 24 hours. Total RNA was collected and Northern hybridizations were
performed as previously described4 using cDNAs of
procollagen
1(I),
2(I),
1(III),
1(IV),
2(IV),
fibronectin, proMMP-2, and proMMP-3 (American Type Culture
Collection).
Statistical Methods
Data are presented as mean±SEM. Statistical
analysis was performed using the Student t test or a
one-way ANOVA followed by the Student-Newman-Keuls test for multiple
comparisons, as appropriate.
| Results |
|---|
|
|
|---|
,
IL-6, or IFN-
for 24 hours had no effect on total protein synthesis
as reflected by [3H]leucine incorporation
(Figure 1A
reduced collagen
synthesis by 43±4% (n=12; P<0.001) and 19±5% (n=5;
P=0.01), respectively (Figure 1A
|
Likewise, in adult rat cardiac fibroblasts, IL-1ß, TNF-
, and IL-6
reduced collagen synthesis by 32±1%, 12±2%, and 11±4%,
respectively (n=3; P<0.05) (Figure 1B
). Treatment
with IL-1ß or TNF-
had no effect on total protein synthesis,
whereas treatment with IL-6 or IFN-
caused modest increases of
16±4% and 14±1%, respectively (n=3; P<0.05) (Figure 1B
). Cell number was not affected by treatment with any of the
cytokines (data not shown). Thus, treatment with IL-1ß and
TNF-
caused selective decreases in collagen synthesis.
Effect of IL-1ß on Collagen mRNA Expression
The IL-1ßmediated decrease in collagen synthesis was further
examined by Northern analyses. Treatment of neonatal
fibroblasts for 24 hours with IL-1ß decreased the expression of mRNA
for procollagens
1(I),
2(I), and
1(III), the
major fibrillar collagen forms in the rat heart (Figure 2
). IL-1ß increased the expression of
mRNA for the nonfibrillar procollagens
1(IV)
and
2(IV) and for fibronectin (Figure 2
). In contrast, FBS increased the expression of the mRNAs for
procollagens
1(I),
2(I), and
1(III), as
well as procollagens
1(IV) and
2(IV) and fibronectin.
|
Effect of Inflammatory Cytokines on MMP Activities
MMP activity in the media of cultures treated with IL-1ß,
TNF-
, IL-6, or IFN-
was determined by in-gel zymography using
gelatin as the substrate. In neonatal fibroblasts, IL-1ß, TNF-
,
and IL-6 each increased total MMP activity (Figures 3A
and 3B
). In adult fibroblasts, IL-1ß
and TNF-
increased total MMP activity (Figure 3C
). Specific
bands corresponding to the molecular weights of MMP-13 (57/48 and 55/45
kDa; type I collagenase), MMP-2 (72/66 kDa; gelatinase A)
and MMP-9 (95/88 kDa; gelatinase B) were increased by treatment with
IL-1ß in both neonatal and adult fibroblasts (Figure 4
). Notably, IL-1ß treatment increased
both the proenzyme and active enzyme bands for MMP-13, MMP-2, and
MMP-9. The identities of the zymographic bands were confirmed by
Western blotting with antibodies to MMP-13, MMP-2, and MMP-9 (data not
shown). IL-1ß treatment also increased a band at
125 to 130 kDa,
which cross-reacted only with pMMP-9.24 All zymographic
MMP activities were inhibited by the metal chelators EDTA and
1,10-phenanthroline, but not the serine protease inhibitor
PMSF (data not shown), confirming their identity as MMPs.
|
|
Effect of IL-1ß on MMP mRNA Expression
The mechanism of MMP activity regulation by IL-1ß was further
examined in neonatal fibroblasts by examining the expression of
proMMP-2 and proMMP-3 mRNAs. ProMMP-2 mRNA level was increased
0.4-fold, indicating that the IL-1ßstimulated increase in MMP-2
activity was at least in part due to increased MMP synthesis (Figure 5
). Likewise, the level of proMMP-3
(stromelysin 1) mRNA was increased 6.9-fold (Figure 5
). MMP-3
activity is not normally seen in gelatin zymography, but MMP-3 activity
is important for activation of MMP-13, which we found to be
activated by IL-1ß. TNF-
also increased expression of
proMMP-3 mRNA, suggesting a mechanism for MMP-13 activation (data not
shown).
|
Role of NO in Mediating the Effects of IL-1ß on Collagen
Turnover
IL-1ß and TNF-
can stimulate the expression of inducible NO
synthase (iNOS) in neonatal fibroblasts (Figure 6A
). However, the ability of IL-1ß to
decrease collagen synthesis or to increase MMP activity was not
attenuated by concomitant treatment with the NOS inhibitor
LNMMA (Figures 6B
and 6C
). Likewise, treatment with the NO donor
SNAP had no effect on basal collagen synthesis or MMP activity (Figures 6B
and 6C
).
|
| Discussion |
|---|
|
|
|---|
have profound effects on collagen metabolism in neonatal
and adult cardiac fibroblasts in vitro. IL-1ß and TNF-
each
decreased collagen synthesis. In the case of IL-1ß, this effect was
associated with decreased expression of the mRNAs for the major
fibrillar procollagens
1(I),
2(I), and
1(III).
IL-1ß and TNF-
also increased MMP activity. Decreased collagen
synthesis was associated with increased expression of the mRNAs for
proMMP-2 and proMMP-3. The effects of IL-1ß on collagen synthesis and
MMP activation were not mediated by NO. The regulation of extracellular
collagen levels is dependent on a dynamic balance between the rates of
synthesis and degradation. The effects of IL-1ß on both sides of this
equation favor a decrease in net fibrillar collagen.
Regulation of Collagen Synthesis
The synthesis of collagen is regulated both transcriptionally and
posttranslationally.25 The decrease in collagen synthesis
occurred without a change in cell number, indicating that it was due to
decreased synthesis at the cellular level. IL-1ß and TNF-
each
decreased collagenase-sensitive
[3H]proline incorporation. This effect occurred
without a decrease in overall protein synthesis as reflected by
[3H]leucine incorporation. In contrast, FBS
increased both total protein synthesis and collagen synthesis. IL-1ß
decreased the levels of mRNA for procollagens
1(I),
2(I), and
1(III), which therefore reflects a decrease in
mRNA transcription and/or a decrease in mRNA stability. In contrast,
IL-1ß increased the expression of the mRNAs for fibronectin and the
nonfibrillar procollagens
1(IV) and
2(IV). In cardiac fibroblasts,
prostaglandin E226 also
decreases collagen synthesis, and phorbol esters decrease the
expression of procollagen
2(I) mRNA.27
On the other hand, several factors, including
endothelin,23 aldosterone,26
mechanical stretch,28 transforming growth
factor-ß1
(TGF-ß1),27 and
angiotensin,26 increase collagen synthesis in
cardiac fibroblasts. TGF-ß1 and
angiotensin also stimulate the proliferation of cardiac
fibroblasts. Thus, the effects of IL-1ß and TNF-
on collagen
synthesis differ qualitatively from several other factors thought to be
involved in the pathogenesis of myocardial remodeling and
failure.29 30
Regulation of Collagen Degradation
Collagen degradation is regulated by the extracellular MMPs. MMP
activity is regulated by both transcriptional and posttranslational
mechanisms. Posttranslational regulation occurs through the
activation of latent proenzymes (proMMPs) by factors such as
serum,31 heparin,32 and
prostaglandin E2.26
Conversely, the activation of MMPs is opposed by the
endogenous TIMPs.10
IL-1ß and TNF-
each increased total MMP activity as measured by
in-gel zymography in neonatal and adult myocytes. IL-1ß increased the
bands corresponding to MMP-13, MMP-2, and MMP-9. The protein levels of
pMMP-13, pMMP-2, and pMMP-9 were increased by Western analysis,
suggesting that the respective increases in zymographic activity were
due, at least in part, to increased protein expression. In support of
this thesis, IL-1ß increased the mRNAs for pMMP-2 and pMMP-3. MMP-3
activity is usually not visualized by in-gel zymography. Because MMP-3
can activate MMP-13, it may have contributed to
posttranslational activation of the MMP cascade. In addition, IL-1ß
may have increased MMP activity by decreasing the expression of TIMP-1
and TIMP-3, as previously shown by Li et al.33
Possible Role of Abnormal Collagen Metabolism in
Myocardial Remodeling
Chronic hemodynamic overload causes remodeling of
the left ventricular (LV) myocardium, which,
over time, may lead to progressive chamber dilation and pump
failure.34 The mechanism responsible for LV dilation in
this setting is not known. At the cellular level there is evidence for
lengthening of individual myocytes.35 However, it has been
observed that the extent of chamber dilation is out of proportion to
the degree of myocyte elongation.36
It has been suggested that chamber dilation might reflect qualitative and/or quantitative changes in extracellular collagen matrix leading to the slippage of myocytes.37 This thesis was suggested by the observation that there is a reduction in collagen cross-links in failing myocardium12 38 and is supported by the finding that MMP activity is increased and TIMP activity is decreased in myocardium obtained from patients with end-stage dilated cardiomyopathy.38 39 40 41 Likewise, MMP activity is increased in animal models of heart failure,42 43 and MMP inhibitors have been shown to decrease the extent of remodeling in 2 modelsdogs with pacing-induced heart failure44 and rats with myocardial infarction.45
Inflammatory Cytokines in Myocardial Remodeling
IL-1ß, IL-6, and TNF-
are elevated in the
myocardium of humans with heart failure.1
Early after myocardial infarction, several cytokines are
elevated transiently, including IL-1ß, TNF-
, IL-6, IFN-
,
TGF-ß1, and
TGF-ß3.3 46 47 48 49 Chronically,
IL-1ß, TNF-
, and IL-6 are elevated in myocardium
remote from the infarction,3 where they are produced
primarily by fibroblasts.48 Of note, the expression of
inflammatory cytokines and MMPs in the heart colocalize to
cardiac fibroblasts.15 48
In vitro, inflammatory cytokines can cause
hypertrophy4 5 50 and
apoptosis7 8 9 of cardiac myocytes. Our data
indicate that IL-1ß and TNF-
also exert potent effects on the
synthesis and degradation of collagen. Thus, it is possible that
inflammatory cytokines cause myocardial remodeling, at least in
part, through their effects on collagen metabolism,
resulting in a depletion of fibrillar collagen. This thesis is
supported by the demonstrations that infusion of TNF-
in normal rats
caused left ventricular dilation and a decrease in cardiac
collagen content16 and that mice overexpressing a
transgene for TNF-
in the heart develop ventricular
dilation.51 52
| Acknowledgments |
|---|
Received November 22, 1999; accepted April 19, 2000.
| References |
|---|
|
|
|---|
2.
Shioi T, Matsumori A, Kihara Y, Inoko M, Ono K,
Iwanaga Y, Yamada T, Iwasaki A, Matsushima K, Sasayama S. Increased
expression of interleukin-1ß and monocyte chemotactic and
activating factor/monocyte chemoattractant protein-1 in the
hypertrophied and failing heart with pressure overload. Circ
Res. 1997;81:664671.
3.
Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S.
Cytokine gene expression after myocardial infarction in rat
hearts: possible implication in left ventricular
remodeling. Circulation. 1998;98:149156.
4. Thaik CM, Calderone A, Takahashi N, Colucci WS. Interleukin-1ß modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest. 1995;96:10931099.
5.
Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW,
Entman M, Mann DL. Tumor necrosis factor-
provokes a
hypertrophic growth response in adult cardiac myocytes.
Circulation. 1997;95:12471252.
6.
McTiernan CF, Lemster BH, Frye C, Brooks S, Combes A,
Feldman AM. Interleukin-1ß inhibits phospholamban gene
expression in cultured cardiomyocytes. Circ Res. 1997;81:493503.
7.
Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V,
Comstock KL, Glembotski CC, Quintana PJ, Sabbadini RA. Tumor necrosis
factor
-induced apoptosis in cardiac myocytes:
involvement of the sphingolipid signaling cascade in cardiac cell
death. J Clin Invest. 1996;98:28542865.[Medline]
[Order article via Infotrieve]
8.
Ing DJ, Zang J, Dzau VJ, Webster KA, Bishopric NH.
Modulation of cytokine-induced cardiac myocyte
apoptosis by nitric oxide, Bak, and Bcl-x. Circ Res. 1999;84:2133.
9.
Arstall MA, Sawyer DB, Fukazawa R, Kelly RA.
Cytokine-mediated apoptosis in cardiac myocytes: the
role of inducible nitric oxide synthase induction and peroxynitrite
generation. Circ Res. 1999;85:829840.
10.
Mann DL, Spinale FG. Activation of matrix
metalloproteinases in the failing human heart: breaking the tie that
binds. Circulation. 1998;98:16991702.
11. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol. 1994;26:279292.[Medline] [Order article via Infotrieve]
12. Weber KT, Pick R, Janicki JS, Gadodia G, Lakier JB. Inadequate collagen tethers in dilated cardiopathy. Am Heart J. 1988;116:16411646.[Medline] [Order article via Infotrieve]
13. Eghbali M, Blumenfeld OO, Seifter S, Buttrick PM, Leinwand LA, Robinson TF, Zern MA, Giambrone MA. Localization of types I, III and IV collagen mRNAs in rat heart cells by in situ hybridization. J Mol Cell Cardiol. 1989;21:103113.[Medline] [Order article via Infotrieve]
14. Eghbali M, Czaja MJ, Zeydel M, Weiner FR, Zern MA, Seifter S, Blumenfeld OO. Collagen chain mRNAs in isolated heart cells from young and adult rats. J Mol Cell Cardiol. 1988;20:267276.[Medline] [Order article via Infotrieve]
15. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 1995;27:12811292.[Medline] [Order article via Infotrieve]
16.
Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko
VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL.
Pathophysiologically relevant concentrations of
tumor necrosis factor-
promote progressive left
ventricular dysfunction and remodeling in rats.
Circulation. 1998;97:13821391.
17.
Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E,
Unemori EN, Lark MW, Amento E, Libby P. Cytokine-stimulated
human vascular smooth muscle cells synthesize a complement of enzymes
required for extracellular matrix digestion. Circ Res. 1994;75:181189.
18.
Yokoo T, Kitamura M. Dual regulation of
IL-1ß-mediated matrix metalloproteinase-9 expression in
mesangial cells by NF-kappa B and AP-1. Am J
Physiol. 1996;270:F123F130.
19.
Li YY, McTiernan CF, Feldman AM. Proinflammatory
cytokines regulate tissue inhibitors of
metalloproteinases and disintegrin metalloproteinase in cardiac cells.
Cardiovasc Res. 1999;42:162172.
20. Calderone A, Thaik CM, Takahashi N, Chang DLF, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest. 1998;101:812818.[Medline] [Order article via Infotrieve]
21. Takahashi N, Calderone A, Izzo NJ Jr, Maki TM, Marsh JD, Colucci WS. Hypertrophic stimuli induce transforming growth factor-ß1 expression in rat ventricular myocytes. J Clin Invest. 1994;94:14701476.
22. Botstein GR, Sherer GK, Leroy EC. Fibroblast selection in scleroderma: an alternative model of fibrosis. Arthritis Rheum. 1982;25:189195.[Medline] [Order article via Infotrieve]
23.
Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT.
Effects of endothelins on collagen turnover in cardiac fibroblasts.
Cardiovasc Res. 1993;27:21302134.
24. Shimamori Y, Watanabe Y, Fujimoto Y. Characterization of gelatinases in human placenta. Biochem Mol Med. 1995;56:8486.[Medline] [Order article via Infotrieve]
25.
Laurent GJ. Dynamic state of collagen: pathways of
collagen degradation in vivo and their possible role in regulation of
collagen mass. Am J Physiol. 1987;252:C1C9.
26. Brilla CG, Maisch B, Zhou G, Weber KT. Hormonal regulation of cardiac fibroblast function. Eur Heart J. 1995;16(suppl C):4550.
27.
Eghbali M, Tomek R, Sukhatme VP, Woods C, Bhambi B.
Differential effects of transforming growth
factor-ß1 and phorbol myristate
acetate on cardiac fibroblasts: regulation of fibrillar collagen mRNAs
and expression of early transcription factors. Circ Res. 1991;69:483490.
28.
Carver W, Nagpal ML, Nachtigal M, Borg TK, Terracio L.
Collagen expression in mechanically stimulated cardiac fibroblasts.
Circ Res. 1991;69:116122.
29. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol. 1997;80:15L25L.[Medline] [Order article via Infotrieve]
30.
Mann DL. Mechanisms and models in heart failure: a
combinatorial approach. Circulation. 1999;100:9991008.
31. Tyagi SC, Kumar S, Glover G. Induction of tissue inhibitor and matrix metalloproteinase by serum in human heart-derived fibroblast and endomyocardial endothelial cells. J Cell Biochem. 1995;58:360371.[Medline] [Order article via Infotrieve]
32. Tyagi SC, Kumar S, Katwa L. Differential regulation of extracellular matrix metalloproteinase and tissue inhibitor by heparin and cholesterol in fibroblast cells. J Mol Cell Cardiol. 1997;29:391404.[Medline] [Order article via Infotrieve]
33. Li YY, McTiernan CF, Feldman AM. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res. 1999;42:162172.
34. Cohn JN. New concepts regarding events that lead to end-stage heart disease. Cardiovasc Drugs Ther. 1995;9(suppl 3):489492.
35.
Gerdes AM, Kellerman SE, Moore JA, Muffly KE, Clark LC,
Reaves PY, Malec KB, McKeown PP, Schocken DD. Structural remodeling of
cardiac myocytes in patients with ischemic
cardiomyopathy. Circulation. 1992;86:426430.
36. Francis GS. Changing the remodeling process in heart failure: basic mechanisms and laboratory results. Curr Opin Cardiol. 1998;13:156161.[Medline] [Order article via Infotrieve]
37.
Olivetti G, Capasso JM, Sonnenblick EH, Anversa P.
Side-to-side slippage of myocytes participates in
ventricular wall remodeling acutely after myocardial
infarction in rats. Circ Res. 1990;67:2334.
38. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF Jr. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy: role of metalloproteinases and pyridinoline cross- links. Am J Pathol. 1996;148:16391648.[Abstract]
39.
Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley
AJ III, Spinale FG. Increased matrix metalloproteinase activity and
selective upregulation in LV myocardium from patients with
end-stage dilated cardiomyopathy.
Circulation. 1998;97:17081715.
40. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem. 1996;155:1321.[Medline] [Order article via Infotrieve]
41.
Li YY, Feldman AM, Sun Y, McTiernan CF. Differential
expression of tissue inhibitors of metalloproteinases in
the failing human heart. Circulation. 1998;98:17281734.
42.
Gilbert SJ, Wotton PR, Tarlton JF, Duance VC, Bailey
AJ. Increased expression of promatrix metalloproteinase-9 and
neutrophil elastase in canine dilated
cardiomyopathy. Cardiovasc Res. 1997;34:377383.
43. Dixon IM, Ju H, Reid NL, Scammell-La Fleur T, Werner JP, Jasmin G. Cardiac collagen remodeling in the cardiomyopathic Syrian hamster and the effect of losartan. J Mol Cell Cardiol. 1997;29:18371850.[Medline] [Order article via Infotrieve]
44.
Spinale FG, Coker ML, Krombach SR, Mukherjee R, Hallak
H, Houck WV, Clair MJ, Kribbs SB, Johnson LL, Peterson JT, Zile MR.
Matrix metalloproteinase inhibition during the development of
congestive heart failure: effects on left ventricular
dimensions and function. Circ Res. 1999;85:364376.
45.
Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH,
Lopez-Anaya A, McClure KF, Mitchell PG, Libby P, Lee RT. Matrix
metalloproteinase inhibition attenuates early left
ventricular enlargement after experimental myocardial
infarction in mice. Circulation. 1999;99:30633070.
46. Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol. 1995;146:419428.[Abstract]
47.
Irwin MW, Mak S, Mann DL, Qu R, Penninger JM, Yan A,
Dawood F, Wen WH, Shou Z, Liu P. Tissue expression and
immunolocalization of tumor necrosis factor-
in postinfarction
dysfunctional myocardium. Circulation. 1999;99:14921498.
48. Yue P, Massie BM, Simpson PC, Long CS. Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am J Physiol. 1998;275(1 pt 2):H250H258.
49. Habib F, Dutka D, Crossman D, Oakley CM, Cleland JG. Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism? Lancet. 1994;344:371373.[Medline] [Order article via Infotrieve]
50. Palmer JN, Hartogensis WE, Patten M, Fortuin FD, Long CS. Interleukin-1ß induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. J Clin Invest. 1995;95:25552564.
51.
Bryant D, Becker L, Richardson J, Shelton J, Franco F,
Peshock R, Thompson M, Giroir B. Cardiac failure in transgenic mice
with myocardial expression of tumor necrosis factor-
.
Circulation. 1998;97:13751381.
52.
Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster
BH, Koretsky AP, Demetris AJ, Feldman AM. Dilated
cardiomyopathy in transgenic mice with
cardiac-specific overexpression of tumor necrosis factor-
.
Circ Res. 1997;81:627635.
This article has been cited by other articles:
![]() |
N. A. Turner, A. Das, P. Warburton, D. J. O'Regan, S. G. Ball, and K. E. Porter Interleukin-1{alpha} stimulates proinflammatory cytokine expression in human cardiac myofibroblasts Am J Physiol Heart Circ Physiol, September 1, 2009; 297(3): H1117 - H1127. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Kandasamy, A. K. Chow, M. A.M. Ali, and R. Schulz Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix Cardiovasc Res, August 20, 2009; (2009) cvp268v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hori and K. Nishida Oxidative stress and left ventricular remodelling after myocardial infarction Cardiovasc Res, February 15, 2009; 81(3): 457 - 464. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Shaw, M. K.H. Shah, S. G. Williams, and J. E. Fildes Immunological mechanisms of pentoxifylline in chronic heart failure Eur J Heart Fail, February 1, 2009; 11(2): 113 - 118. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Zavadzkas, R. A. Plyler, S. Bouges, C. N. Koval, W. T. Rivers, C. U. Beck, E. I. Chang, R. E. Stroud, R. Mukherjee, and F. G. Spinale Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causes myocardial remodeling and dysfunction in aging mice Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1394 - H1402. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Spinale, C. N. Koval, A. M. Deschamps, R. E. Stroud, and J. S. Ikonomidis Dynamic Changes in Matrix Metalloprotienase Activity Within the Human Myocardial Interstitium During Myocardial Arrest and Reperfusion Circulation, September 30, 2008; 118(14_suppl_1): S16 - S23. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bujak, M. Dobaczewski, K. Chatila, L. H. Mendoza, N. Li, A. Reddy, and N. G. Frangogiannis Interleukin-1 Receptor Type I Signaling Critically Regulates Infarct Healing and Cardiac Remodeling Am. J. Pathol., July 1, 2008; 173(1): 57 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Spruill, A. S. Lowry, R. E. Stroud, C. E. Squires, I. M. Mains, E. C. Flack, C. Beck, J. S. Ikonomidis, A. J. Crumbley, P. J. McDermott, et al. Membrane-type-1 matrix metalloproteinase transcription and translation in myocardial fibroblasts from patients with normal left ventricular function and from patients with cardiomyopathy Am J Physiol Cell Physiol, October 1, 2007; 293(4): C1362 - C1373. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zhang, M.-X. Zhang, Y. H. Shen, J. K. Burks, Y. Zhang, J. Wang, S. A. LeMaire, K. Yoshimura, H. Aoki, J. S. Coselli, et al. TNF-{alpha} Suppresses Prolyl-4-Hydroxylase {alpha}1 Expression via the ASK1-JNK-NonO Pathway Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1760 - 1767. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Meldrum, R. Misseri, P. Metcalfe, C. A. Dinarello, K. L. Hile, and D. R. Meldrum TNF-{alpha} neutralization ameliorates obstruction-induced renal fibrosis and dysfunction Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1456 - R1464. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Goruppi, R. D. Patten, T. Force, and J. M. Kyriakis Helix-Loop-Helix Protein p8, a Transcriptional Regulator Required for Cardiomyocyte Hypertrophy and Cardiac Fibroblast Matrix Metalloprotease Induction Mol. Cell. Biol., February 1, 2007; 27(3): 993 - 1006. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. H. Mountain, M. Singh, B. Menon, and K. Singh Interleukin-1beta increases expression and activity of matrix metalloproteinase-2 in cardiac microvascular endothelial cells: role of PKC{alpha}/beta1 and MAPKs Am J Physiol Cell Physiol, February 1, 2007; 292(2): C867 - C875. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. W. Cheng, K. Obata, M. Kuzuya, H. Izawa, K. Nakamura, E. Asai, T. Nagasaka, M. Saka, T. Kimata, A. Noda, et al. Elastolytic Cathepsin Induction/Activation System Exists in Myocardium and Is Upregulated in Hypertensive Heart Failure Hypertension, November 1, 2006; 48(5): 979 - 987. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Rutschow, J. Li, H.-P. Schultheiss, and M. Pauschinger Myocardial proteases and matrix remodeling in inflammatory heart disease Cardiovasc Res, February 15, 2006; 69(3): 646 - 656. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-Y. Wang, M. R. Bergman, A. P. Nguyen, S. Turcato, P. M. Swigart, M. C. Rodrigo, P. C. Simpson, J. S. Karliner, D. H. Lovett, and A. J. Baker Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility Cardiovasc Res, February 15, 2006; 69(3): 688 - 696. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Trescher, O. Bernecker, B. Fellner, M. Gyongyosi, R. Schafer, S. Aharinejad, R. DeMartin, E. Wolner, and B. K. Podesser Inflammation and postinfarct remodeling: Overexpression of I{kappa}B prevents ventricular dilation via increasing TIMP levels Cardiovasc Res, February 15, 2006; 69(3): 746 - 754. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Matsusaka, M. Ikeuchi, S. Matsushima, T. Ide, T. Kubota, A. M. Feldman, A. Takeshita, K. Sunagawa, and H. Tsutsui Selective disruption of MMP-2 gene exacerbates myocardial inflammation and dysfunction in mice with cytokine-induced cardiomyopathy Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1858 - H1864. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. Cowling, X. Zhang, V. C. Reese, M. Iwata, D. Gurantz, W. H. Dillmann, and B. H. Greenberg Effects of cytokine treatment on angiotensin II type 1A receptor transcription and splicing in rat cardiac fibroblasts Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1176 - H1183. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Rude, T.-A. S. Duhaney, G. M. Kuster, S. Judge, J. Heo, W. S. Colucci, D. A. Siwik, and F. Sam Aldosterone Stimulates Matrix Metalloproteinases and Reactive Oxygen Species in Adult Rat Ventricular Cardiomyocytes Hypertension, September 1, 2005; 46(3): 555 - 561. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ohtsuka, K. Inoue, Y. Hara, N. Morioka, K. Ohshima, J. Suzuki, A. Ogimoto, Y. Shigematsu, and J. Higaki Serum markers of angiogenesis and myocardial ultrasonic tissue characterization in patients with dilated cardiomyopathy Eur J Heart Fail, June 1, 2005; 7(4): 689 - 695. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Becker Yin and Yang of MCP-1 Circ. Res., April 29, 2005; 96(8): 812 - 814. [Full Text] [PDF] |
||||
![]() |
A.H. Schoneveld, M.M. Oude Nijhuis, B. van Middelaar, J.D. Laman, D.P.V. de Kleijn, and G. Pasterkamp Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development Cardiovasc Res, April 1, 2005; 66(1): 162 - 169. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Banfi, V. Cavalca, F. Veglia, M. Brioschi, S. Barcella, L. Mussoni, L. Boccotti, E. Tremoli, P. Biglioli, and P. Agostoni Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure Eur. Heart J., March 1, 2005; 26(5): 481 - 488. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Lalu, E. Pasini, C. J. Schulze, M. Ferrari-Vivaldi, G. Ferrari-Vivaldi, T. Bachetti, and R. Schulz Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart Eur. Heart J., January 1, 2005; 26(1): 27 - 35. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Kong, M. T. Longaker, and H. P. Lorenz Cyclophilin C-associated Protein Is a Mediator for Fibronectin Fragment-induced Matrix Metalloproteinase-13 Expression J. Biol. Chem., December 31, 2004; 279(53): 55334 - 55340. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tazaki, K. Minoguchi, T. Yokoe, K. T. R. Samson, H. Minoguchi, A. Tanaka, Y. Watanabe, and M. Adachi Increased Levels and Activity of Matrix Metalloproteinase-9 in Obstructive Sleep Apnea Syndrome Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1354 - 1359. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Burton, R. L. Bailey, D. Jeffries, D. C. W. Mabey, and M. J. Holland Cytokine and Fibrogenic Gene Expression in the Conjunctivas of Subjects from a Gambian Community Where Trachoma Is Endemic Infect. Immun., December 1, 2004; 72(12): 7352 - 7356. [Abstract] [Full Text] [PDF] |
||||
![]() |
V Bjerkeli, B Halvorsen, J K Damas, I Nordoy, A Yndestad, P Aukrust, and S S Froland Expression of matrix metalloproteinases in patients with Wegener's granulomatosis Ann Rheum Dis, December 1, 2004; 63(12): 1659 - 1663. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. Porter, N. A. Turner, D. J. O'Regan, and S. G. Ball Tumor necrosis factor {alpha} induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin Cardiovasc Res, December 1, 2004; 64(3): 507 - 515. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sun, F. Dawood, W.-H. Wen, M. Chen, I. Dixon, L. A. Kirshenbaum, and P. P. Liu Excessive Tumor Necrosis Factor Activation After Infarction Contributes to Susceptibility of Myocardial Rupture and Left Ventricular Dysfunction Circulation, November 16, 2004; 110(20): 3221 - 3228. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Meiners, B. Hocher, A. Weller, M. Laule, V. Stangl, C. Guenther, M. Godes, A. Mrozikiewicz, G. Baumann, and K. Stangl Downregulation of Matrix Metalloproteinases and Collagens and Suppression of Cardiac Fibrosis by Inhibition of the Proteasome Hypertension, October 1, 2004; 44(4): 471 - 477. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Xie, M. Singh, and K. Singh Differential Regulation of Matrix Metalloproteinase-2 and -9 Expression and Activity in Adult Rat Cardiac Fibroblasts in Response to Interleukin-1{beta} J. Biol. Chem., September 17, 2004; 279(38): 39513 - 39519. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Stawowy, C. Margeta, H. Kallisch, N. G Seidah, M. Chretien, E. Fleck, and K. Graf Regulation of matrix metalloproteinase MT1-MMP/MMP-2 in cardiac fibroblasts by TGF-{beta}1 involves furin-convertase Cardiovasc Res, July 1, 2004; 63(1): 87 - 97. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nian, P. Lee, N. Khaper, and P. Liu Inflammatory Cytokines and Postmyocardial Infarction Remodeling Circ. Res., June 25, 2004; 94(12): 1543 - 1553. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. KJAeR Role of Extracellular Matrix in Adaptation of Tendon and Skeletal Muscle to Mechanical Loading Physiol Rev, April 1, 2004; 84(2): 649 - 698. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Xie, M. Singh, D. A. Siwik, W. L. Joyner, and K. Singh Osteopontin Inhibits Interleukin-1{beta}-stimulated Increases in Matrix Metalloproteinase Activity in Adult Rat Cardiac Fibroblasts: ROLE OF PROTEIN KINASE C-{zeta} J. Biol. Chem., December 5, 2003; 278(49): 48546 - 48552. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. B Jones, D. C Sane, and D. M Herrington Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome Cardiovasc Res, October 1, 2003; 59(4): 812 - 823. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Horstmann, P. Kalb, J. Koziol, H. Gardner, and S. Wagner Profiles of Matrix Metalloproteinases, Their Inhibitors, and Laminin in Stroke Patients: Influence of Different Therapies Stroke, September 1, 2003; 34(9): 2165 - 2170. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hayashidani, H. Tsutsui, M. Ikeuchi, T. Shiomi, H. Matsusaka, T. Kubota, K. Imanaka-Yoshida, T. Itoh, and A. Takeshita Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1229 - H1235. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Wilson, S. L. Moainie, J. M. Baskin, A. S. Lowry, A. M. Deschamps, R. Mukherjee, T. S. Guy, M. G. St John-Sutton, J. H. Gorman III, L. H. Edmunds Jr, et al. Region- and Type-Specific Induction of Matrix Metalloproteinases in Post-Myocardial Infarction Remodeling Circulation, June 10, 2003; 107(22): 2857 - 2863. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Fernandez-Real and W. Ricart Insulin Resistance and Chronic Cardiovascular Inflammatory Syndrome Endocr. Rev., June 1, 2003; 24(3): 278 - 301. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kaufmann, A. Mueller, A. Voigt, H. D. Carl, A. Gursche, J. Zacher, G. Stein, and G. Hein Hydroxypyridinium collagen crosslinks in serum, urine, synovial fluid and synovial tissue in patients with rheumatoid arthritis compared with osteoarthritis Rheumatology, February 1, 2003; 42(2): 314 - 320. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Y. Siu, W. M. Lee, and C. Y. Cheng The Interplay of Collagen IV, Tumor Necrosis Factor-{alpha}, Gelatinase B (Matrix Metalloprotease-9), and Tissue Inhibitor of Metalloproteases-1 in the Basal Lamina Regulates Sertoli Cell-Tight Junction Dynamics in the Rat Testis Endocrinology, January 1, 2003; 144(1): 371 - 387. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. F. Bronzwaer, C. Heymes, C. A. Visser, and W. J. Paulus Myocardial fibrosis blunts nitric oxide synthase-related preload reserve in human dilated cardiomyopathy Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H10 - H16. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Peng, D. Gurantz, V. Tran, R. T. Cowling, and B. H. Greenberg Tumor Necrosis Factor-{alpha}-Induced AT1 Receptor Upregulation Enhances Angiotensin II-Mediated Cardiac Fibroblast Responses That Favor Fibrosis Circ. Res., December 13, 2002; 91(12): 1119 - 1126. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tsuruda, G. Boerrigter, B. K. Huntley, J. A. Noser, A. Cataliotti, L. C. Costello-Boerrigter, H. H. Chen, and J. C. Burnett Jr Brain Natriuretic Peptide Is Produced in Cardiac Fibroblasts and Induces Matrix Metalloproteinases Circ. Res., December 13, 2002; 91(12): 1127 - 1134. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pauschinger, K. Chandrasekharan, J. Li, W. Poller, M. Noutsias, C. Tschope, and H.-P. Schultheiss Inflammation and extracellular matrix protein metabolism: two sides of myocardial remodelling Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I49 - I53. [Abstract] [PDF] |
||||
![]() |
J. Li, P. Lothar Schwimmbeck, C. Tschope, S. Leschka, L. Husmann, S. Rutschow, F. Reichenbach, M. Noutsias, U. Kobalz, W. Poller, et al. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction Cardiovasc Res, November 1, 2002; 56(2): 235 - 247. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zaragoza, E. Soria, E. Lopez, D. Browning, M. Balbin, C. Lopez-Otin, and S. Lamas Activation of the Mitogen Activated Protein Kinase Extracellular Signal-Regulated Kinase 1 and 2 by the Nitric Oxide-cGMP-cGMP-Dependent Protein Kinase Axis Regulates the Expression of Matrix Metalloproteinase 13 in Vascular Endothelial Cells Mol. Pharmacol., October 1, 2002; 62(4): 927 - 935. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Deten, H. C. Volz, W. Briest, and H.-G. Zimmer Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats Cardiovasc Res, August 1, 2002; 55(2): 329 - 340. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Falk, P.M. Soccal, J. Grunenfelder, G. Hoyt, T. Walther, and R.C. Robbins Regulation of matrix metalloproteinases and effect of MMP-inhibition in heart transplant related reperfusion injury Eur. J. Cardiothorac. Surg., July 1, 2002; 22(1): 53 - 58. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. Bradham, G. Moe, K. A. Wendt, A. A. Scott, A. Konig, M. Romanova, G. Naik, and F. G. Spinale TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1288 - H1295. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Spinale Matrix Metalloproteinases: Regulation and Dysregulation in the Failing Heart Circ. Res., March 22, 2002; 90(5): 520 - 530. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Werner, F. Kheradmand, R. R. Isberg, and Z. Werb Phagocytosis mediated by Yersinia invasin induces collagenase-1 expression in rabbit synovial fibroblasts through a proinflammatory cascade J. Cell Sci., March 11, 2002; 114(18): 3333 - 3343. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. Bradham, B. Bozkurt, H. Gunasinghe, D. Mann, and F. G. Spinale Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective Cardiovasc Res, March 1, 2002; 53(4): 822 - 830. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hilfiker-Kleiner, A. Hilfiker, B. Schieffer, D. Engel, D. L Mann, K. C Wollert, and H. Drexler TNF{alpha} decreases {alpha}MHC expression by a NO mediated pathway: role of E-box transcription factors for cardiomyocyte specific gene regulation Cardiovasc Res, February 1, 2002; 53(2): 460 - 469. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Marian On Genetics, Inflammation, and Abdominal Aortic Aneurysm : Can Single Nucleotide Polymorphisms Predict the Outcome? Circulation, May 8, 2001; 103(18): 2222 - 2224. [Full Text] [PDF] |
||||
![]() |
E. A. Palmieri, G. Benincasa, F. Di Rella, C. Casaburi, M. G. Monti, G. De Simone, L. Chiariotti, L. Palombini, C. B. Bruni, L. Sacca, et al. Differential expression of TNF-alpha , IL-6, and IGF-1 by graded mechanical stress in normal rat myocardium Am J Physiol Heart Circ Physiol, March 1, 2002; 282(3): H926 - H934. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |